Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.
Please provide your email address to receive an email when new articles are posted on . Results of a randomized control trial of patients with advanced cirrhosis without recent fluoroquinolone therapy ...
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell ...
FRANKLIN LAKES, N.J., June 23, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from ...
Leading US liver transplant center completes its first two implantationsMount Sinai Hospital and University of Pennsylvania also complete multiple implantations Dartmouth Hitchcock Medical Center and ...
THE problem of the accumulation of fluid in the peritoneal cavity in association with cirrhosis of the liver has for many years presented a challenge to the surgeon, since it has always been tempting ...
Clinical-stage biotech BioVie (NASDAQ:BIVI) announced Monday that the company halted patient enrollment in Phase 2b clinical trial for ascites candidate BIV201 after generating "compelling" data from ...
THE problem of wasting ascites occurring in patients with cirrhosis of the liver is unsolved — both the pathogenesis of the ascites and its reliable cure. Recent observations have indicated the ...
MAY 9, 2025, NEW YORK – A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies. Led by Ludwig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results